Journal of General Internal Medicine

, Volume 32, Issue 10, pp 1156–1159 | Cite as

Rhabdomyolysis and AKI with Atorvastatin and Sitagliptin Use in the Setting of Low 25-Hydroxyvitamin D Levels

  • Rupinder Singh Buttar
  • Jasveen Batra
  • Jacqueline Kreimerman
  • Melissa Aleta
  • Michal L. Melamed
Clinical Practice: Clinical Vignettes


We report a case of an 86-year-old woman admitted to the hospital with rhabdomyolysis and acute kidney injury 3 weeks after starting sitagliptin while on long-term atorvastatin therapy. She also had low levels of 25-hydroxyvitamin D and mild chronic kidney disease, which may have contributed to the development of rhabdomyolysis. A review of the literature reveals four previous reports of this drug interaction in elderly patients, some with underlying kidney disease.


sitagliptin statins vitamin D rhabdomyolysis drug interaction acute kidney injury 



Dr. Melamed is supported by grants R01 DK102952 and R34 DK102174 from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. A previous version was presented as a poster at the National Kidney Conference in Boston in 2016.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they do not have a conflict of interest.


  1. 1.
    Bhome R, Penn H. Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction. Diabet Med. 2012;29(5):693–694.CrossRefPubMedGoogle Scholar
  2. 2.
    Kao DP, Kohrt HE, Kugler J. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. Diabet Med. 2008;25(10):1229–30.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    DiGregorio RV, Pasikhova Y. Rhabdomyolysis caused by a potential sitagliptin-lovastatin interaction. Pharmacotherapy. 2009;29(3):352–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Campos-Davila E, Puerto-Alonso J, Perez-Vazquez G, Ramos-Baez J, Marquez-Fernandez E, Guerra-Estevez D. PS-006 Rhabdomyolysis possiblz provoked by a sitagliptin-atorvastatin interaction. Eur J Hosp Pharm: Sci Pract. 2014;21(Suppl 1):A145–6.Google Scholar
  5. 5.
    Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13(2):160–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Plosker GL. Sitagliptin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014;74(2):223–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Ovesjo ML, Skilving I, Bergman P, Rane A, Ekstrom L, Bjorkhem-Bergman L. Low vitamin D levels and genetic polymorphism in the vitamin D receptor are associated with increased risk of statin-induced myopathy. Basic Clin Pharmacol Toxicol. 2016;118(3):214–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Khayznikov M, Hemachrandra K, Pandit R, Kumar A, Wang P, Glueck CJ. Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin D supplementation. N Am J Med Sci. 2015;7(3):86–93.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Bergman AJ, Cote J, Yi B, et al. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007;30(7):1862–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Pharmacology/ToxicologyReviewandEvaluation-NDA21–995.2006; Accessed 30 May 2017.
  11. 11.
    Bergman AJ, Cote J, Maes A, et al. Effect of sitagliptin on the pharmacokinetics of simvastatin. J Clin Pharmacol. 2009;49(4):483–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Cerra M, Luo WL, Li SX, et al. The effects of simvastatin on the pharmacokinectics of sitagliptin. J Popul Ther Clin Pharmacol. 2012;19(3):e356–60.PubMedGoogle Scholar
  13. 13.
    Scheen AJ. Pharmacokinetic evaluation of atorvastatin and sitagliptin in combination for the treatment of type 2 diabetes. Expert Opin Drug Metab Toxicol. 2012;8(6):745–58.CrossRefPubMedGoogle Scholar
  14. 14.
    Alagona P, Jr. Pitavastatin: evidence for its place in treatment of hypercholesterolemia. Core Evid. 2010;5:91–105.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Lee P, Greenfield JR, Campbell LV. Vitamin D insufficiency—a novel mechanism of statin-induced myalgia? Clin Endocrinol. 2009;71(1):154–5.CrossRefGoogle Scholar
  16. 16.
    De Boland AR, Boland RL. Non-genomic signal transduction pathway of vitamin D in muscle. Cell Signal. 1994;6(7):717–24.CrossRefPubMedGoogle Scholar
  17. 17.
    Ceglia L, Harris SS. Vitamin D and its role in skeletal muscle. Calcif Tissue Int. 2013;92(2):151–162.CrossRefPubMedGoogle Scholar
  18. 18.
    Pleasure D, Wyszynski B, Sumner A, et al. Skeletal muscle calcium metabolism and contractile force in vitamin D-deficient chicks. J Clin Investig. 1979;64(5):1157–67.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Wang Z, Schuetz EG, Xu Y, Thummel KE. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4. J Steroid Biochem Mol Biol. 2013;136:54–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Drocourt L, Ourlin JC, Pascussi JM, Maurel P, Vilarem MJ. Expression of CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human hepatocytes. J Biol Chem. 2002;277(28):25125–32.CrossRefPubMedGoogle Scholar
  21. 21.
    Bhattacharyya S, Bhattacharyya K, Maitra A. Possible mechanisms of interaction between statins and vitamin D. QJM: Mon J Assoc Phys. 2012;105(5):487–491.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2017

Authors and Affiliations

  • Rupinder Singh Buttar
    • 1
  • Jasveen Batra
    • 1
  • Jacqueline Kreimerman
    • 1
  • Melissa Aleta
    • 1
  • Michal L. Melamed
    • 1
  1. 1.Department of Medicine/NephrologyAlbert Einstein College of Medicine/Montefiore Medical CenterBronxUSA

Personalised recommendations